1.26 USD
+0.07 (+5.88%)
1.26 USD
0 (0%)
We assign a fundamental rating of 2 out of 10 to IFRX. IFRX was compared to 533 industry peers in the Biotechnology industry. IFRX has a bad profitability rating. Also its financial health evaluation is rather negative. IFRX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year IFRX has reported negative net income.
IFRX had a negative operating cash flow in the past year.
IFRX had negative earnings in each of the past 5 years.
IFRX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IFRX (-61.55%) is comparable to the rest of the industry.
IFRX has a Return On Equity (-88.40%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.55% | ||
| ROE | -88.4% | ||
| ROIC | N/A |
ROA(3y)-41.63%
ROA(5y)-39.97%
ROE(3y)-49.99%
ROE(5y)-47.39%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IFRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IFRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IFRX has more shares outstanding
The number of shares outstanding for IFRX has been increased compared to 5 years ago.
The debt/assets ratio for IFRX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.08, we must say that IFRX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.08, IFRX is doing worse than 64.98% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that IFRX is not too dependend on debt financing.
IFRX has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.08 |
ROIC/WACCN/A
WACC7.19%
2.3 Liquidity
IFRX has a Current Ratio of 3.33. This indicates that IFRX is financially healthy and has no problem in meeting its short term obligations.
IFRX has a Current ratio of 3.33. This is comparable to the rest of the industry: IFRX outperforms 40.26% of its industry peers.
A Quick Ratio of 3.06 indicates that IFRX has no problem at all paying its short term obligations.
The Quick ratio of IFRX (3.06) is worse than 60.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.33 | ||
| Quick Ratio | 3.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 38.78% over the past year.
IFRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -62.49%.
EPS 1Y (TTM)38.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)-62.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.65%
3.2 Future
The Earnings Per Share is expected to grow by 11.30% on average over the next years. This is quite good.
The Revenue is expected to grow by 88.88% on average over the next years. This is a very strong growth
EPS Next Y15.34%
EPS Next 2Y11.28%
EPS Next 3Y6.31%
EPS Next 5Y11.3%
Revenue Next Year-74.12%
Revenue Next 2Y84.57%
Revenue Next 3Y95.58%
Revenue Next 5Y88.88%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IFRX. In the last year negative earnings were reported.
Also next year IFRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.28%
EPS Next 3Y6.31%
5. Dividend
5.1 Amount
IFRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.26
+0.07 (+5.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners24.95%
Inst Owner Change6.46%
Ins Owners6.38%
Ins Owner ChangeN/A
Market Cap85.36M
Revenue(TTM)63.20K
Net Income(TTM)-40.10M
Analysts84.29
Price Target11.8 (836.51%)
Short Float %2.14%
Short Ratio0.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.91%
Min EPS beat(2)-16.54%
Max EPS beat(2)-11.29%
EPS beat(4)2
Avg EPS beat(4)17.88%
Min EPS beat(4)-16.54%
Max EPS beat(4)68.63%
EPS beat(8)3
Avg EPS beat(8)1.85%
EPS beat(12)7
Avg EPS beat(12)12.99%
EPS beat(16)10
Avg EPS beat(16)16.59%
Revenue beat(2)0
Avg Revenue beat(2)-45.63%
Min Revenue beat(2)-67.47%
Max Revenue beat(2)-23.79%
Revenue beat(4)0
Avg Revenue beat(4)-73.03%
Min Revenue beat(4)-100.86%
Max Revenue beat(4)-23.79%
Revenue beat(8)1
Avg Revenue beat(8)-66.61%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)179.31%
PT rev (3m)170%
EPS NQ rev (1m)6.25%
EPS NQ rev (3m)5.26%
EPS NY rev (1m)0%
EPS NY rev (3m)0.4%
Revenue NQ rev (1m)-12.89%
Revenue NQ rev (3m)-12.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1167.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.63 | ||
| P/tB | 1.63 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.77
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.55% | ||
| ROE | -88.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-41.63%
ROA(5y)-39.97%
ROE(3y)-49.99%
ROE(5y)-47.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 29.73% | ||
| Cap/Sales | 206.65% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.33 | ||
| Quick Ratio | 3.06 | ||
| Altman-Z | -6.08 |
F-Score1
WACC7.19%
ROIC/WACCN/A
Cap/Depr(3y)17.06%
Cap/Depr(5y)14.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y15.34%
EPS Next 2Y11.28%
EPS Next 3Y6.31%
EPS Next 5Y11.3%
Revenue 1Y (TTM)-62.49%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-80.65%
Revenue Next Year-74.12%
Revenue Next 2Y84.57%
Revenue Next 3Y95.58%
Revenue Next 5Y88.88%
EBIT growth 1Y20.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.02%
EBIT Next 3Y-0.62%
EBIT Next 5YN/A
FCF growth 1Y-31.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.19%
OCF growth 3YN/A
OCF growth 5YN/A
INFLARX NV / IFRX FAQ
Can you provide the ChartMill fundamental rating for INFLARX NV?
ChartMill assigns a fundamental rating of 2 / 10 to IFRX.
What is the valuation status for IFRX stock?
ChartMill assigns a valuation rating of 0 / 10 to INFLARX NV (IFRX). This can be considered as Overvalued.
Can you provide the profitability details for INFLARX NV?
INFLARX NV (IFRX) has a profitability rating of 1 / 10.
Can you provide the financial health for IFRX stock?
The financial health rating of INFLARX NV (IFRX) is 3 / 10.